This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ImmunoVEX<sup>HSV2</sup>

Amgen, Inc.

Drug Names(s): ImmunoVEX<sup>HSV2</sup>

Description: ImmunoVEXHSV2 is a live attenuated genital herpes vaccine based on a proprietary engineered form of the causative agent of genital herpes, HSV-2, from which genes that collectively interfere with the functions of immune system have been deleted. The proteins encoded by these genes aid wild type HSV-2 in evading the body's immune system.

ImmunoVEXHSV2 expresses all but four of the approximately 80 HSV-2 proteins, maximizing the breadth of the anti-HSV immune response generated, but without the genes encoding for these immune-inhibiting proteins.

ImmunoVEXHSV2 has been evaluated in the industry-standard preclinical model of genital herpes, in which it completely prevented disease, suggesting that ImmunoVEXHSV2 may be more potent in humans than other HSV-2 vaccines for which published data is available. The vaccine also considerably reduced the level of viral shedding following exposure, which if this translates to the clinical setting, may also reduce any window of infectivity from an infected individual.

Deal Structure: In January 2011, Amgen and BioVex Group announced that the companies have entered into a definitive acquisition agreement under which Amgen has agreed to acquire BioVex Group.

Under terms of the agreement, Amgen will pay up to $1 billion: $425 million in cash at closing and up to $575 million in additional payments upon the achievement of certain regulatory and sales milestones. Following the completion of the transaction, BioVex will become a wholly owned subsidiary of Amgen. This acquisition closed in March 2011.


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug